This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inter Parfums (IPAR) Ups '23 EPS Guidance on Q2 Earnings Beat
by Zacks Equity Research
Inter Parfums' (IPAR) second-quarter 2023 results reflect higher earnings and sales on growth across Europe and U.S.-based operations. Management raises the 2023 earnings view.
Inter Parfums (IPAR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inter Parfums (IPAR) delivered earnings and revenue surprises of 22.47% and 0.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inter Parfums (IPAR) Queued for Q2 Earnings: Things to Note
by Zacks Equity Research
Inter Parfums' (IPAR) second-quarter 2023 performance will likely reflect gains from the company's brand strength across U.S. and European operations.
Upstart (UPST) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Upstart's (UPST) second-quarter 2023 performance is likely to have benefited from recent additions to its product portfolio amid a challenging macro environment and tightening from funding partners.
Is a Surprise Coming for Inter Parfums (IPAR) This Earnings Season?
by Zacks Equity Research
Inter Parfums (IPAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3D Systems (DDD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
3D Systems' (DDD) second-quarter results are likely to reflect strong demand for healthcare products and stabilization in industrial division.
Factors Likely to Drive Purple Innovation's (PRPL) Q2 Earnings
by Zacks Equity Research
Purple Innovation's (PRPL) Q2 results are likely to reflect gains from the innovative product line and efforts to reduce costs amid inflationary pressures and a demand shift.
Medifast (MED) Queued for Q2 Earnings: Things to Consider
by Zacks Equity Research
Medifast's (MED) second-quarter 2023 performance will likely reflect challenges related to customer acquisition and higher cost inflation.
Nu Skin (NUS) Lowers 2023 Guidance Despite Q2 Earnings Beat
by Zacks Equity Research
Nu Skin (NUS) reports sequential improvements in Q2 results, driven by the Mainland China and Rhyz segments. However, macro-economic factors pose challenges in the key markets.
Is Vertiv Holdings (VRT) Likely to Surpass Q2 Earnings Estimates?
by Zacks Equity Research
Vertiv Holdings' (VRT) second-quarter performance is likely to have been aided by solid demand for its digital infrastructure and continuity solutions.
What's on the Cards for Monster Beverage (MNST) in Q2 Earnings?
by Zacks Equity Research
Monster Beverage's (MNST) Q2 results are expected to reflect gains from continued strength in the energy drinks category and robust product innovation plans.
Things You Need to Know Before Corteva's (CTVA) Q2 Earnings
by Zacks Equity Research
A favorable product mix and pricing gains are likely to have contributed to Corteva's (CVTA) Q2 performance. However, currency headwinds and higher input costs are likely to have ailed.
Cloudflare (NET) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cloudflare's (NET) second-quarter performance is likely to have been aided by solid demand for security solutions and the benefits of its recurring subscription-based business model.
Fortinet (FTNT) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Fortinet's (FTNT) second-quarter 2023 earnings are likely to have been aided by the strong adoption of Security Fabric, cloud and SD-WAN offerings.
Procter & Gamble (PG) Rises on Q4 Earnings Beat, Robust View
by Zacks Equity Research
Procter & Gamble's (PG) Q4 results reflect strong gains from its pricing actions, robust demand, improved sales and margins, and a positive product mix.
Inter Parfums (IPAR) Ups 2023 Guidance on Robust Q2 Sales
by Zacks Equity Research
Inter Parfums' (IPAR) sales increase year over year in second-quarter 2023. Management raises its top-line view for 2023.
COTY Inks Agreement to Offload 3.6% of Its Stake in Wella
by Zacks Equity Research
COTY inks a letter of intent to divest part of its stake in Wella to IGF Wealth Management. This is likely to help the company meet its leverage goal toward 3X as it exits CY23.
Inter Parfums (IPAR) Gains on Partnerships & Product Launches
by Zacks Equity Research
Inter Parfums (IPAR) focuses on product launches to boost brand strength. The company's strength in strategic partnerships is driving growth.
Inter Parfums (IPAR) Secures Roberto Cavalli Fragrance License
by Zacks Equity Research
Inter Parfums (IPAR) remains committed to innovation and meeting the evolving demands of fragrance enthusiasts worldwide.
Watch These 4 Cosmetics Stocks as Industry Looks Radiant
by Zacks Equity Research
The Zacks Cosmetics industry players benefit from their focus on innovation and online strength amid favorable demand. Coty (COTY), el.f. Beauty (ELF), Inter Parfums (IPAR) and Helen of Troy (HELE) look well-placed.
Inter Parfums (IPAR) Up 0.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inter Parfums (IPAR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inter Parfums (IPAR) Exhibits Strong Prospects Amid Risks
by Zacks Equity Research
Inter Parfums (IPAR) is poised to benefit from the booming fragrance market, strategic partnerships and product launches. However, escalating operating expenses remain a concern.
Boot Barn (BOOT) Q4 Earnings Top Estimates, Sales Rise Y/Y
by Zacks Equity Research
Boot Barn (BOOT) fourth-quarter fiscal 2023 results reflect a year-over-year increase in both the top line and bottom line.
Will Strong Pricing Action Aid Church & Dwight's (CHD) Growth?
by Zacks Equity Research
Church & Dwight's (CHD) strong pricing efforts, strategic buyouts and favorable online sales act as upsides against macroeconomic headwinds.
The Zacks Analyst Blog Highlights Celsius Holdings, The Clorox, Lamb Weston Holdings, Coty and Inter Parfums
by Zacks Equity Research
Celsius Holdings, The Clorox, Lamb Weston Holdings, Coty and Inter Parfums are part of the Zacks top Analyst Blog.